<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0"
     xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
     xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /opt/grobid/grobid-home/schemas/xsd/Grobid.xsd"
     xmlns:xlink="http://www.w3.org/1999/xlink">
  <teiHeader xml:lang="en">
    <encodingDesc>
      <appInfo>
        <application version="0.5.4" ident="GROBID" when="2020-06-24T12:06+0000">
          <ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
        </application>
      </appInfo>
    </encodingDesc>
    <fileDesc>
      <titleStmt>
        <title level="a" type="main">The ultralong-acting intraocular pressure reduction produced by JV-GL1 is mediated entirely by prostanoid EP2 receptors, according to gene deletion</title>
      </titleStmt>
      <publicationStmt>
        <publisher>Authorea, Inc.</publisher>
        <availability status="unknown"><p>Copyright Authorea, Inc.</p>
        </availability>
        <date type="published" when="2020-05-05">May 5, 2020</date>
      </publicationStmt>
      <sourceDesc>
        <biblStruct>
          <analytic>
            <author>
              <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jacques</forename><surname>Bertrand</surname></persName>
            </author>
            <author>
              <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Woodward</surname></persName>
            </author>
            <author>
              <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><surname>Sherwood</surname></persName>
            </author>
            <author>
              <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><surname>Coleman</surname></persName>
            </author>
            <author>
              <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jenny</forename><surname>Wang</surname></persName>
            </author>
            <author>
              <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Darryl</forename><surname>Overby</surname></persName>
            </author>
            <title level="a" type="main">The ultralong-acting intraocular pressure reduction produced by JV-GL1 is mediated entirely by prostanoid EP2 receptors, according to gene deletion</title>
          </analytic>
          <monogr>
            <imprint>
              <publisher>Authorea, Inc.</publisher>
              <date type="published" when="2020-05-05">May 5, 2020</date>
            </imprint>
          </monogr>
          <idno type="DOI">10.22541/au.158531795.54392142</idno>
          <note>Posted on Authorea 27 Mar 2020 -CC BY 4.0 -https://doi.org/10.22541/au.158531795.54392142 -This a preprint and has not been peer reviewed. Data may be preliminary.</note>
        </biblStruct>
      </sourceDesc>
    </fileDesc>
    <profileDesc>
      <abstract>
        <div xmlns="http://www.tei-c.org/ns/1.0"><head>Abstract</head><p>BACKGROUND AND PURPOSE: A single dose of JV-GL1 lowers intraocular pressure (IOP) for a week according to previous</p></div>
      </abstract>
    </profileDesc>
  </teiHeader>
  <text xml:lang="en">
    <body>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Primary open-angle glaucoma is the second leading cause of blindness <ref type="bibr" target="#b29">(Resnikoff et al. , 2004)</ref>. Firstline glaucoma therapy typically consists of eye drops that lower intraocular pressure (IOP) and containing prostaglandin analogues such as bimatoprost, latanoprost, and travoprost <ref type="bibr" target="#b32">(Sambhara and Aref, 2014)</ref>. These drugs primarily target the uveoscleral tissues <ref type="bibr">(Schachtschabel, Lindsey and Weinreb, 2000;</ref><ref type="bibr">Winkler and Fautsch, 2014)</ref>, lowering resistance to aqueous humour outflow, reducing IOP, and thereby protecting retinal ganglion cells from pressure induced damage. Once daily dosing is required to effectively manage IOP, however 25% of patients are non-responders <ref type="bibr" target="#b34">(Scherer, 2002;</ref><ref type="bibr" target="#b31">Sakurai et al. , 2014)</ref>, and poor patient compliance is commonplace <ref type="bibr" target="#b23">(Okeke et al. , 2009;</ref><ref type="bibr" target="#b1">Boland et al. , 2014)</ref>. Poor compliance correlates with more severe visual field loss <ref type="bibr" target="#b38">(Sleath et al. , 2012)</ref>. It follows that a relaxed dosing regimen, for example once or twice weekly with a long acting drug, may improve compliance and treatment outcomes accordingly.</p><p>JV-GL1 (PGN 9856-isopropyl ester), was recently reported as a highly selective and potent EP 2 receptor agonist <ref type="bibr">(Colemanet al. , 2018)</ref>, which profoundly lowers IOP in Cynomolgus monkeys for an unprecedented duration of 5-10 days after a single dose <ref type="bibr" target="#b46">(Woodward, et al. , 2019a)</ref>. The well-researched EP 2 agonist, butaprost <ref type="bibr" target="#b21">(Nilsson et al. , 2006)</ref>, and the more contemporary EP 2 agonists taprenepag <ref type="bibr" target="#b26">(Prasanna et al. , 2011)</ref> and omnidenepag isopropyl <ref type="bibr" target="#b6">(Fuwa et al. , 2018)</ref> have comparatively short 24 hour durations of action.</p><p>Understanding the mechanism behind the uniquely long-acting ocular hypotensive effect of JV-GL1 is of interest in the development of superior ocular hypotensive agents. Given the lack of correlation between the ultra-long duration of action of JV-GL1 and its relatively short bioavailability in the eye <ref type="bibr" target="#b46">(Woodward et al., 2019a)</ref>, an EP 2 receptor mediated mechanism seemed unlikely. In the present investigations, we examined the IOP-lowering effect of JV-GL1 in ocular normotensive and hypertensive mice. Ocular hypertension was induced in mice using a recently developed method of locally injected dexamethasone eluting nanoparticles <ref type="bibr" target="#b0">(Agrahari, 2017;</ref><ref type="bibr" target="#b42">Wang et al. , 2018)</ref>. The role of the EP 2 receptor in mediating the IOP effects of JV-GL1 was then investigated using EP 2 receptor deleted mice <ref type="bibr" target="#b13">(Kennedy et al. , 1999)</ref>.</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals</head><p>All procedures on living mice were carried out in compliance with the Imperial College Statement for Use of Animals in Research, under a UK Home Office project license. All animal care and experimental protocols adhered to (a) the US National Research Council's Guide for the Care and Use of laboratory animals, (b) the ARVO guidelines and (c) the BJP guidelines for experiments involving animals and animal tissues. Animal studies are reported in compliance with the ARRIVE guidelines <ref type="bibr" target="#b14">(Kilkenny et al., 2010;</ref><ref type="bibr" target="#b19">McGrath and Lilley, 2015)</ref>.</p><p>Prostaglandin E receptor 2 (EP 2 ) knock-out mice (B6.129-Ptger2 tm1Brey /J) were purchased from The Jackson Laboratory (Bar Harbour, Maine, USA), supplied via Charles River Ltd. UK. These mice were originally created in a C57BL/6J background via homologous recombination and exhibit increased sensitivity to dietary salt induced hypertension and produce small litter sizes due to a defect in embryo implantation <ref type="bibr" target="#b13">(Kennedy et al. , 1999)</ref>. We therefore adopted the following breeding strategy.Ptger2 +/-breeding pairs were purchased from the Jackson Laboratories. Male Ptger2 -/-offspring were then crossed with femalePtger2 +/-offspring to producePtger2 -/-individuals. Separately,Ptger +/+ offspring were crossed withPtger2 +/-offspring to producePtger2 +/+ individuals.Ptger2 -/-andPtger2 +/+ individuals were thus separated by 1 generation. For experiments that used only WT mice, C57BL/6J mice were purchased from The Jackson Laboratories and used without breeding. Mice were housed in individually ventilated cages with a 12-hour light/dark cycle, maintained at 21°C, with food and water ad libitum. Following arrival from the commercial supplier, mice were allowed to acclimatise for a week before any regulatory procedures were performed.</p><p>Genotyping followed the recommended protocol provided by the Jackson Laboratory for B6.129-Ptger2 tm1Brey /J mice. Genotyping was carried out on DNA extracted from ear tissue sampled at weaning, following the manufacturer's instructions (Express Extract, Kapa Biosystems, Cambridge, MA, USA). KAPA2G Robust HotStart ReadyMix (Kapa Biosystems) was used for PCR reactions. Knock-out sense primer (ATTAAGGGCCAGCTCATTCC), wild-type sense primer (TGCTCATGCTCTTCGCTATG) and common antisense primer (CGTACTCCCCGTAGTTGAGC), with annealing temperatures of 60°C and 28 cycles, yielded predicted products of 300 bp for knock-outs and 165 bp for wild-types (Supplemental <ref type="figure" target="#fig_2">Figure  1D)</ref>. PCR products were resolved by gel electrophoresis (1% agarose) in the presence of a DNA gel stain (SYBR Safe, Invitrogen, Carlsbad,CA, USA). Bands were visualized on an imaging station (Biospectrum 500, UVP, Upland, CA, USA).</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Preparation of dexamethasone-eluting nanoparticles</head><p>Initial attempts to replicate the method described by <ref type="bibr" target="#b0">Agrahari et al . (Agrahari, 2017)</ref> to synthesise dexamethasone loaded nanoparticles using the penta-block co-polymer PGA-PCL-PEG-PCL-PGA (poly(glycolic acid)-poly (caprolactone)-poly (ethylene glycol)-poly (caprolactone)-poly (glycolic acid) were unsuccessful. In our hands we could not dissolve the co-polymer in dichloromethane, perhaps due to the crystallinity of high molecular weight poly-glycolic acid <ref type="bibr" target="#b9">(Hacker and Mikos, 2011)</ref>. Therefore, we chose to use a variant of the penta-block co-polymer described by <ref type="bibr" target="#b40">Tamboli et al . (Tamboli, Mishra and Mitra, 2013)</ref>, which was (poly(d,l )lactide-poly (caprolactone)-poly(ethylene-glycol)-poly (caprolactone)-poly(d,l )lactide (PDLLA-PCL-PEG-PCL-PDLLA).</p><p>Nanoparticles were synthesised from the PDLLA-PCL-PEG-PCL-PDLLA co-polymer using the oil-in-water solvent evaporation technique <ref type="bibr" target="#b18">(McCall and Sirianni, 2013)</ref>. 75 mg of penta-block co-polymer (AK099, PolySciTech, Akina Inc. West Lafayette, IN, USA) and 5 mg of dexamethasone (D4209, Sigma-Aldrich St. Louis, MO, USA) were added to 1.2 ml of ethyl acetate and vortexed into solution. The solution was added dropwise to 2 ml of vortexing 0.1% aqueous D-alpha-tocopherol polyethylene glycol 1000 succinate (E-TPGS, 57668, Sigma-Aldrich St. Louis, MO, USA). Immediately after mixing, the pre-emulsion was probe ultrasonicated (Branson 450 digital Sonifier, Branson Ultrasonic Corporation, CT, USA) in 10 x 30 second bursts at 20% power on ice. Between bursts, the emulsion was allowed to cool for 10 seconds. The emulsion was immediately added dropwise to 45 ml of 0.3% aqueous E-TPGS on a magnetic stirrer (300-400 rpm) for overnight solvent evaporation at room temperature. Nanoparticles were recovered by ultracentrifugation at 20,000 RPM for 1 hour at 4°C and washed 3 times with distilled water to remove E-TPGS and un-entrapped dexamethasone. Nanoparticles were lyophilized for 72 hours with trehalose, a lyoprotecterant <ref type="bibr">(Zhouet al. , 2013)</ref>, in a weight ratio of 0.5:1, trehalose:polymer (A19434.06, Alfa Aesar Haverhill, MA, USA), and stored at 4°C for further studies. Synthesis of unloaded nanoparticles was identical with the omission of dexamethasone. Average particle size was 167 nm <ref type="bibr">[145,</ref><ref type="bibr">189]</ref> (mean, [95% CI]) based on 150 measurements of individual particles in six scanning electron microscope images (JSM-5610, JEOL Ltd. Akishima, Tokyo, Japan) using the 'measure' function in ImageJ <ref type="bibr" target="#b35">(Schneider, Rasband and Eliceiri, 2012)</ref>.</p><p>We used mass spectrometry to measure the mass of dexamethasone contained within 5 mg of loaded nanoparticles. Nanoparticles were first dissolved in DMSO. An Agilent 6130 Quadrupole LC-MS coupled to an Agilent 1260 Infinity LC using a 150 X 4.6 mm Phenomenex Gemini NX-C18 column with a 110Å110Å pore size and 5 m particle size was used to quantify dexamethasone concentration. Ultrapure water and acetonitrile, each containing 0.1% (v/v) formic acid (VWR) by volume, were used for the mobile phase at a flow rate of 1 ml/min. Samples were eluted with a gradient of 95% (v/v) water to 95% (v/v) acetonitrile over 10 minutes. The electrospray source was operated with a capillary voltage of 3.2 kV and a cone voltage of 25 V with nitrogen used as the nebulizer and desolvation gas at a total flow of 600 l/h. Detection was between 100-1000 Da in both positive and negative ionisation mode.</p><p>On the day of use, lyophilised nanoparticles were re-suspended in sterile PBS by bath sonication to a concentration of 0.25 mg/ml dexamethasone. Injections were performed under general anaesthesia induced by 5 minutes exposure to 4% isoflurane and 1 l/min oxygen in an anaesthetic chamber. Following loss of consciousness, confirmed by toe pinch, mice were transferred to a Bain co-axial circuit fitted with a mouse nose-cone to maintain anaesthesia. Mice received topical anaesthesia (Lidocaine hydrochloride 4%, Chauvin Pharma, Aubenas, France) immediately prior to injection of 20 l nanoparticle suspension into the periocular tissue of each eye using a Hamilton syringe and a 30 gauge needle. Mice recovered in a 36°C chamber and were housed in groups of 5 for the remainder of the study.</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Preparation of Ophthalmic Solutions</head><p>JV-GL1 isopropyl ester (and de-esterified JV-GL1) were supplied by JeniVision Inc. Irvine, CA, USA). Butaprost was purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). Both drugs were dissolved in 100% EtOH and made up to 0.01% in vehicle, composed of 0.2 m sterile filtered PBS, 0.2% DMSO and 1% polysorbate 80.</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Investigating the IOP effects of JV-GL1</head><p>The effects of JV-GL1 on IOP were investigated in four experiments. In all studies IOP was measured under general anaesthesia, bilaterally in each mouse between 09:00 AM and 12:00 noon using a commercial rebound tonometer (TonoLab; Icare, Helsinki, Finland). For each time point IOP was calculated as the mean of three consecutive tonometer readings, each containing 6 rebound events, as previously described <ref type="bibr" target="#b24">(Overby et al. , 2014)</ref>. We designed 4 experiments to test the effect of JV-GL1 on IOP.</p><p>The first experiment investigated the IOP effect of JV-GL1 in normotensive Ptger2 -/-mice (11 males &amp; 3 females, 10.7 [10-12] weeks old, mean [95% CI]) andPtger2 +/+ mice (6 males &amp; 10 females, 12.6 [12-13] weeks old). Baseline IOP was established prior to unilateral administration of either 0.01% JV-GL1 (Ptger2 -/-n=7,Ptger2 +/+ n=9) or 0.01% butaprost (Ptger2 -/-n=7,Ptger2 +/+ n=7), with contralateral eyes receiving vehicle. IOP was measured at 3 and 24 hours, with an additional measurement at 48 hours for the JV-GL1 treated group. Data were presented as the mean difference between paired treated and untreated eyes (IOP).</p><p>The second experiment investigated the IOP effect of JV-GL1 in wildtype C57BL/6J mice (10 week old males, n=18) that had been rendered ocular hypertensive by subconjunctival injection of dexamethasone-eluting nanoparticles. Baseline IOP was established over two time points prior to bilateral nanoparticle injection. IOP was measured after two weeks to establish the level of ocular hypertension induced by the glucocorticoid, referred to as the pre-treatment time point. Mice were treated bilaterally with either 0.01% JV-GL1 (n=9) or 0.01% butaprost (n=9). IOP was measured in both eyes at 3 hours, followed by measurements at 2, 6 and 9 days. JV-GL1 treated eyes were additionally measured at 12 and 16 days, whereupon a second challenge with 0.01% JV-GL1 was administered to one eye, with contralateral receiving vehicle. After 19 days, IOP was measured for a final time and mice culled for outflow facility measurements. Data was presented as the mean change in IOP from the pre-treatment time point (δIOP).</p><p>The third experiment aimed to compare the IOP-lowering effect of JV-GL1 between normotensive versus hypertensive WT C57BL/6J littermates (n=8 vs 9; 10 week old males). Normotensive individuals received unloaded nanoparticles. Baseline IOP was established once prior to bilateral injection of either dexamethasone loaded or unloaded nanoparticles into the periocular tissues. IOP was measured after 1 week to establish the level of ocular hypertension. One eye was then treated with 0.01% JV-GL1 with contralateral eye receiving vehicle. IOP was measured in both eyes at 3 and 24 hours, followed by measurements at 4 and 6 days. Data were presented as the mean difference between paired treated and untreated eyes (IOP).</p><p>The fourth experiment investigated the IOP effect of JV-GL1 inPtger2 -/-mice (5 males &amp; 3 females, 12.5 <ref type="bibr">[11,</ref><ref type="bibr">14]</ref> weeks old) and Ptger2 +/+ mice (5 males &amp; 5 females, 13 [12, 14.1] weeks old) that had been rendered steroid induced ocular hypertensive. Baseline IOP was established once prior to bilateral injection of dexamethasone loaded nanoparticles into the periocular tissues. IOP was measured after one week to establish the level of ocular hypertension. One eye was then treated with 0.01% JV-GL1 with contralateral eye receiving vehicle. IOP was measured in both eyes at 3 and 24 hours, followed by measurements at 4, 6 and 11 days. Data were presented as the mean difference between paired treated and untreated eyes (IOP).</p><p>In all IOP studies, the following statistical analyses were applied. Normality was checked by the KolgomorovSmirnov test, equity of variances between groups was determined by Levene's test, and statistical significance between groups over multiple time points was established via a two-factor ANOVA. Errors are presented as 95% confidence intervals.</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Measurement of Conventional Outflow Facility</head><p>In all perfusion studies mice were culled humanely by cervical dislocation, eyes enucleated immediately after death and outflow facility measured simultaneously in paired eyes using theiPerfusion system, as previously described <ref type="bibr" target="#b36">(Sherwood et al. , 2016)</ref>. Briefly, eyes were glued to a support platform submerged in PBS regulated at 35°C. The ocular anterior chambers were cannulated with 33-gauge bevelled needles (NanoFil, NF33BV-2, World Precision Instruments) attached to micro-manipulators and equilibrated for 30 minutes at 9 mmHg. Perfusate comprised 0.2 m filtered DBG (PBS including divalent cations and 5.5 mM glucose). Flow was measured at pressure steps from 5 to 17 mmHg in 7 steps. The steady state criterion per step was 1 minute of &lt;0.1 nl/min/mmHg/min variation in ratio of flow rate to pressure. Pressure steps that failed to reach steady state were excluded from further analysis, paired eyes with 4 or more successful steps were analysed. A Savitzky-Golay filter (60secs, first order) was applied to the digital pressure and flow data before calculation to increase precision without distorting the signal tendencies.</p><p>Mean steady state flow Q and pressure P for each included pressure step were calculated over a 4-minute window and fit by the relationship Q = C r P P r β P C r represents outflow facility at a reference pressure P r (8 mmHg) and β characterizes the non-linearity of theQ-P relationship. Average relative change in C r was compared between contralateral treated and control eyes (mean ± 95% CI) using a weighted t -test of the log-transformed data as described previously <ref type="bibr" target="#b36">(Sherwood et al. , 2016)</ref>.</p><p>Acute effects on outflow facility were determined by perfusing DBG containing 100 nM de-esterified JV-GL1 directly into the anterior chamber of normotensive C57BL/6J mouse eyes (n=7) and compared to paired vehicle perfused contralateral eyes. All pairs tested met the stability criteria. Long-term effects of topical JV-GL1 treatment on outflow facility were determined in steroid induced ocular hypertensive C57BL/6J mice (n=9) following unilateral treatment with 0.01% JV-GL1, with contralateral eyes receiving vehicle, outflow facility was measured ex vivo 3 days later. All pairs tested met the stability criteria.</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>The effect of JV-GL1 in normotensive mice</head><p>As JV-GL1 is an EP 2 agonist <ref type="bibr" target="#b3">(Coleman et al., 2018;</ref><ref type="bibr" target="#b46">Woodward et al., 2019a)</ref>, our first aim was to measure the IOP-lowering effect of JV-GL1 in normotensive mice that express EP 2 (Ptger2 +/+ ) versus mice that lack EP 2 (Ptger2 -/-). BetweenPtger2 +/+ andPtger2 -/-, there was no significant difference in baseline IOP nor outflow facility (Supplemental <ref type="figure" target="#fig_2">Figure 1)</ref>. Three hours after unilateral treatment with JV-GL1 (0.01%, 10 l), IOP was reduced in Ptger2 +/+ mice (IOP =-3.1 [-4.1, -2.1] mmHg; mean [95% CI]; P &lt;0.0001; n=9 mice) with respect to the vehicle-treated contralateral eye <ref type="figure" target="#fig_2">(Fig. 1A)</ref>. InPtger2 -/-mice, however, there was no significant IOP reduction following treatment with JV-GL1 after 3 hrs (IOP = 0.8 [-0.4, 2.0] mmHg; P =1, n=7). By 24 hours, IOP in the treated eye of Ptger2 +/+ mice had returned to baseline and was not statistically different from IOP in the control eye (IOP = 0.0 [-1.0, 1.0] mmHg, P =1, n=9). Thus, the IOP-lowering effect of JV-GL1 requires Ptger2 and lasts for less than 24 hrs, at least in normotensive mice.</p><p>We also compared the effects of JV-GL1 against the archetypical EP 2 agonist butaprost <ref type="figure" target="#fig_2">(Fig. 1A)</ref>. .5] mmHg; P =1; n=7). The IOP reduction in response to butaprost was not significantly different from that of JV-GL1 at 3 hrs (P =1), and neither drug had an observable effect on IOP at 24 hrs. Thus, the magnitude and duration of IOP-lowering in response to JV-GL1 appears to be similar to that of butaprost in ocular normotensive mice.</p><p>To investigate the physiological mechanism of IOP reduction, we then examined the effect of JV-GL1 on pressure-dependent outflow. We observed no significant effect of de-esterified JV-GL1 (100 nM) on outflow facility when perfused directly into enucleated eyes of C57BL/6J mice (relative to contralateral vehicleperfused eyes), which expressPtger2 (-6% [-22, 13], P =0.4, n=5 pairs; <ref type="figure" target="#fig_2">Fig. 1B)</ref>. Thus, consistent with other EP 2 agonists that are thought to lower IOP primarily by increasing unconventional outflow <ref type="bibr" target="#b21">(Nilsson et al. ,2006;</ref><ref type="bibr" target="#b47">Woodward, et al. , 2019b)</ref>, JV-GL1 does not appear to have an acute effect on outflow facility.</p><p>The effect of JV-GL1 in ocular hypertensive mice</p><p>We then examined the effect of JV-GL1 in C57BL/6J mice with ocular hypertension. We induced ocular hypertension by periocular injection of dexamethasone-eluting nanoparticles given bilaterally. This elevated IOP by 4.2 [3.5, 4.9] mmHg relative to baseline, and this elevation was sustained over 2 weeks following a single nanoparticle injection without a significant loss of body weight (n=18; Supplemental <ref type="figure">Figure 2</ref>). Ocular hypertensive mice were treated with a single topical drop of JV-GL1 (10 l, 0.01%) given bilaterally. As with the normotensive mice, IOP was reduced after 3 hrs relative to the pre-treatment IOP (δIOP = -2.3 [-3.3, -1.2] mmHg; P =0.01; n=9 mice, <ref type="figure">Fig. 2A</ref>). However, unlike the normotensives, the IOP reduction persisted for up to 6 days when δIOP = -2.8 [-3.7, -2.0] mmHg (P =0.001; n=9). Thus, a single treatment of JV-GL1 reduces IOP for several days in mice with steroid-induced ocular hypertension, in contrast to results from a different cohort of normotensive mice where the IOP-lowering effects of JV-GL1 lasted for less than 1 day <ref type="figure" target="#fig_2">(Fig. 1A)</ref> After 9 days, the effects of JV-GL1 in hypertensives had diminished and IOP had returned to pre-treatment levels (δIOP = -0.5 [-1.5, 0.5] mmHg; P =1; n=9), which were still elevated with respect to baseline due to dexamethasone. We then administered a second dose of JV-GL1 (10 l, 0.01%) to one randomly-chosen eye of each mouse, while the contralateral eye received vehicle ( <ref type="figure">Fig. 2A second red arrow )</ref>. After 3 days, IOP was again reduced in the JV-GL1-treated eye by -2.3 [-3.4, -1.2] mmHg (P= 0.04; n=9) relative to the contralateral eye, demonstrating at least partial repeatability. The mice were then euthanized 3 days after JV-GL1 treatment, and eyes were enucleated to measure outflow facility. In eyes treated with JV-GL1, outflow facility was not statistically different from that in contralateral vehicle-treated eyes (18% <ref type="bibr">[-7, 50</ref>], P =0.2, n=9 pairs; <ref type="figure">Fig 2B)</ref>. Thus, the IOP reduction observed in response to JV-GL1 in ocular hypertensive mice does not appear to coincide with an increase in outflow facility, similar to the absence of a facility response observed in normotensive mice.</p><p>To confirm that the long-lasting IOP reduction of JV-GL1 is not attributable to cohort differences between the normotensive and hypertensive groups, we compared the effects of JV-GL1 between wildtype littermates with or without ocular hypertension. Hypertension was induced by bilateral periocular injection of dexamethasone-eluting nanoparticles, while normotensives received a bilateral injection of unloaded nanoparticles. In the group receiving dexamethasone-eluting nanoparticles, IOP increased by 4.7 In normotensive mice, however, the IOP reduction was short-lived and was observed only at 3 hrs ([?]IOP = -1.6 [-2.7, -0.5] mmHg, P =0.08; n=9). This confirms that a single dose of JV-GL1 is capable of reducing IOP for several days in mice with steroid-induced ocular hypertension, but the effect of JV-GL1 is relatively short-lived in normotensive C57BL/6J littermates.</p><p>To examine whether the long duration of JV-GL1 action was distinct from typical EP 2 agonism, we treated ocular hypertensive mice with a single bilateral dose of butaprost (10 l, 0.01%). Butaprost reduced IOP after 3 hrs ([?]IOP = -2.5 [-4.2, -1.0] mmHg;P =0.07; n=9; <ref type="figure">Fig. 2A</ref>) but, as observed in normotensive mice, IOP returned to pre-treatment values by 2 days ([?]IOP = -0.8 [-1.5, 0.0] mmHg; P =0.6; n=9). This reveals that the long-lasting IOP reduction attributable to JV-GL1 under hypertensive conditions is distinct from that of typical EP 2 agonists.</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>The role of EP 2 in the long-lasting IOP reduction of JV-GL1 in ocular hypertensive mice</head><p>It is possible that the long-lasting IOP reduction in steroid-hypertensive mice is attributable to off-target effects of JV-GL1 apart from EP 2 (e.g., by inhibiting the steroid response). To explore this possibility, we compared the effects of JV-GL1 between Ptger2 -/-andPtger2 +/+ littermates, all with steroid-induced ocular hypertension. A single bilateral periocular injection of dexamethasone-eluting nanoparticles increased IOP by 4.9 [3.8, 5.9] mmHg over 1 week (n=18; Supplemental <ref type="figure" target="#fig_3">Figure 3)</ref>, with no significant differences observed between Ptger2 -/-andPtger2 +/+ littermates.</p><p>In hypertensive Ptger2 +/+ mice, a single unilateral dose of JV-GL1 (10 l, 0.01%) reduced IOP after 3 hrs by -4.2 [-5.6, -2.9] mmHg relative to the vehicle-treated contralateral eye (P &lt;0.0001; n=10 mice, <ref type="figure" target="#fig_4">Fig. 4</ref>). IOP reduction persisted for up to 4 days, when IOP = -2.6 [-3.3, -1.8] mmHg (P =0.02; n=10) but was undetectable by 6 days, when IOP= -1.6 [-2.8, -0.4] mmHg (P =0.7; n=10). In contrast, JV-GL1 had no effect on Ptger2 -/-mice at 3 hours, when IOP= 0.67 [-0.3, 1.6] mmHg (P =1; n=8) nor any other time point. Thus, the long-lasting effect of JV-GL1 on IOP reduction does not appear to involve off-target effects, but appears to require EP 2 receptor expression.</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>The most important facet of JV-GL1 pharmacology is arguably its ultra-long duration of action <ref type="bibr" target="#b46">(Woodward et al ., 2019a)</ref>. The present studies have demonstrated that this prolonged effect on intraocular pressure is entirely mediated by a single pharmacological entity, the EP 2 receptor. Class selective long-acting β 2 -agonists (LABAs) and muscarinic antagonists (LAMAs) have previously been discovered <ref type="bibr" target="#b45">(Wold et al., 2019;</ref><ref type="bibr">Wendell et al., 2020)</ref> but their clinical dosing regimen is once daily, even when used in combination <ref type="bibr" target="#b16">(Maqsood et al., 2019)</ref>. For JV-GL1, a once weekly dosing regimen is feasible. Further research on JV-GL1 and the EP 2 receptor may lead to a wide range of small molecules dosed once-weekly that offer improved disease control and lower drug costs. At this juncture, the existing data suggests JV-GL1 may be an important new drug for women's health and inflammation <ref type="bibr">(Coleman et al ., 2019)</ref>. For glaucoma, the data indicate that JV-GL1 is a realistic proposition for a breakthrough drug in treating glaucoma <ref type="bibr">(Colemanet al ., 2018;</ref><ref type="bibr" target="#b46">Woodward et al., 2019a)</ref>.</p><p>The long-acting effects of JV-GL1 on IOP in monkeys extend far beyond time points when detectable levels of the drug can be measured in anterior segment tissues of the eye <ref type="bibr" target="#b46">(Woodward, et al. , 2019a)</ref>. JV-GL1 was designed as an EP 2 receptor agonist and the long acting effects of a week or more were quite unexpected, given that the ocular hypotensive duration of action of the numerous EP 2 agonist family is essentially one day <ref type="bibr" target="#b47">(Woodward,et al. , 2019b)</ref>. This raised the possibility that the effects of JV-GL1 on IOP occurred as a result of two separate pharmacological activities; an initial EP 2 receptor mediated effect followed by a secondary long-acting phase that was independent of EP 2 receptors. In order to address this question, we studied the effects of JV-GL1 in gene deleted mice <ref type="bibr" target="#b30">(Saeki et al. , 2009</ref>). Our studies demonstrate that the entire duration of ocular hypotensive action of JV-GL1 is EP 2 receptor mediated.</p><p>A single topical application of 0.01% JV-GL1 significantly reduced IOP in both ocular normotensive and steroid-induced ocular hypertensive mice after 3 hours. However, only steroid treated mice exhibited a long-term pressure reduction, persisting for 4 to 6 days. JV-GL1 was incapable of reducing IOP in mice lacking the EP 2 receptor under both ocular normotensive and steroid ocular hypertensive conditions. Conventional interpretation of G-protein coupled receptor signalling would suggest that upon ligand binding to the EP 2 receptor Gα s coupling activates adenylate cyclase which converts adenosine triphosphate to the second messenger, cyclic adenosine monophosphate (cAMP) <ref type="bibr" target="#b28">(Regan et al. , 1994;</ref><ref type="bibr">Pierceet al. , 1995)</ref>. The cAMP-dependent pathway promotes matrix metalloproteinase (MMP's) secretion <ref type="bibr" target="#b37">(Shim, Kim and Ju, 2017</ref>). MMP's break down extracellular matrix material in the outflow tissues of the eye, reducing resistance and lowering IOP <ref type="bibr" target="#b21">(Nilsson et al. , 2006)</ref>.</p><p>In this study, topical JV-GL1 did not significantly affect outflow facility in the steroid ocular hypertensive mouse eye, nor in ocular normotensive mouse eyes perfused with de-esterified JV-GL1 over an acute time-scale. A study using cellular dielectric spectroscopy found JV-GL1 to have high activity in human ciliary muscle cells but little activity in human trabecular meshwork cells (3.9 nM vs &gt;10 M, EC 50 values respectively) <ref type="bibr" target="#b46">(Woodward, et al. , 2019a)</ref>. This suggests a uveoscleral mechanism of action for JV-GL1, which correlates with the minimal effects on outflow facility observed in this study and with the mechanism of action proposed for the standard and most studied EP 2 agonist, butaprost <ref type="bibr">(Nilssonet al. , 2006)</ref>. Our perfusion results largely corroborate those obtained from perfusion studies in monkeys, where JV-GL1 did not significantly affect outflow facility. However, in monkeys JV-GL1 significantly increases uveoscleral outflow, as measured by fluorophotometry, and significantly reduces inflow by 20% over an acute timescale <ref type="bibr" target="#b46">(Woodward, et al. , 2019a)</ref>. A limitation of measuring outflow facility in enucleated mouse eyes is that inflow is essentially terminated once the eye is removed and the pressure independent nature of the uveoscleral pathway makes it challenging to measure using a pressure controlled perfusion system. Thus, any effect JV-GL1 may have on inflow or uveoscleral outflow cannot be measured. Unfortunately in monkey studies, inflow measurements were not continued over the time-course of IOP measurements, and the relationship between a reduction in inflow and IOP suppression remains unanswered.</p><p>In monkeys, JV-GL1 exhibited long-term IOP effects in both ocular normotensive and laser-induced ocular hypertensive animals, and demonstrated considerably greater pressure reduction <ref type="bibr" target="#b46">(Woodward et al. , 2019a)</ref> compared to the observations made in this study with mice. These inconsistencies may simply be due to species differences. The relative size of the ciliary muscle is much smaller in mice than in primates <ref type="bibr" target="#b15">(Ko and Tan, 2013</ref>) as mice do not accommodate for vision <ref type="bibr" target="#b41">(Tamm and Lutjen-Drecoll, 1996)</ref>. If JV-GL1 is thought to work primarily via the uveoscleral route, then the more developed ciliary muscle of the monkey, which is in frequent use and therefore containing greater amounts of extracellular matrix material, would be expected to respond better to remodelling effects of MMP's than the more vestigial ciliary muscle of the mouse.</p><p>Alternatively, it may be the different methods employed to induce ocular hypertension. Unlike laser-induced ocular hypertension, the steroid induced ocular hypertensive model relies on the persistent presence of dexamethasone in the eye, eluting from periocular depots of dexamethasone loaded nanoparticles. Steroid ocular hypertension is brought about by dexamethasone induced changes in extracellular matrix deposition and stiffness in the trabecular meshwork <ref type="bibr" target="#b24">(Overby et al. , 2014;</ref><ref type="bibr" target="#b27">Raghunathan et al. , 2015)</ref>. Increased extracellular matrix deposition is likely due to dexamethasone inhibiting MMP's, either through inhibition of transcription factors <ref type="bibr" target="#b5">(Forster et al. , 2007)</ref> or by inducing tissue inhibitors of matrix metalloproteases (MMP's) <ref type="bibr" target="#b48">(Xu et al. , 2001)</ref>. Dexamethasone may have similar effects on the uveoscleral pathway. MMP's 2, 3 &amp; 9 were found to be significantly reduced in ciliary body explants treated with dexamethasone, with MMP-3 eliminated after 72 hours of dexamethasone treatment <ref type="bibr" target="#b4">(el-Shabrawi et al. , 2000)</ref>. MMP-3 can break down a diverse range of extracellular matrix components <ref type="bibr" target="#b17">(Matrisian, 1990)</ref>. What is more, dexamethasone has been shown to inhibit the production of endogenous prostaglandins in human trabecular meshwork cells and scleral fibroblasts <ref type="bibr" target="#b7">(Gerritsen et al. , 1986)</ref>.</p><p>Prostaglandins have been shown to induce MMP production in the ciliary body <ref type="bibr" target="#b4">(el-Shabrawi et al. , 2000)</ref>. These MMP's are thought to be released into the aqueous and diffuse into the ciliary muscle where they break down extracellular matrix components between the longitudinal fibres of the ciliary muscle, allowing less restricted flow into the choroid <ref type="bibr" target="#b22">(Ocklind, 1998)</ref>. Consequently, we can speculate that JV-GL1 in the steroid ocular hypertensive mouse model would have to compete against the pro-fibrotic effects of constant dexamethasone delivery to the eye, limiting its ability to lower IOP to the same degree observed in the laser-induced ocular hypertensive monkey model, where no dexamethasone is present.</p><p>It is of interest that JV-GL1 has an effect on inflow in monkeys, as this has not been demonstrated with any other EP 2 agonists to date <ref type="bibr" target="#b47">(Woodward, et al. , 2019b)</ref>. The most studied EP 2 agonist, butaprost, is efficacious at lowering IOP but has a short duration of action, with no effect on inflow and no effect on conventional outflow facility. The entirety of butaprost effects appear to be mediated by changes in uveoscleral outflow, specifically ciliary muscle resistance <ref type="bibr" target="#b21">(Nilsson et al. , 2006)</ref>. Therefore, JV-GL1 behaves somewhat differently when compared to other EP 2 agonists. Aqueous flow can be reduced by direct activators of adenylate cyclase such as forskolin <ref type="bibr" target="#b2">(Caprioli et al. , 1984)</ref> and cholera toxin <ref type="bibr" target="#b8">(Gregory et al. , 1981)</ref>, via a cAMP-dependent process. In the latter case, reduction in IOP persisted for 6 days after a single intravitreal injection.</p><p>It is, of course, highly unlikely that JV-GL1 is directly and/or irreversibly activating adenylate cyclase. However, recent research has disrupted the conventional view of G-protein coupled receptor signalling, whereby active receptor conformations engage and activate only one of four classes of cytoplasmic heterotrimeric G-proteins (Gα i/o, Gα s , Gα q/11 and Gα 12 ) and a more promiscuous model, whereby receptors can bind to more than one G-protein subtype, eliciting multiple G-protein dependent signalling events has emerged <ref type="bibr" target="#b39">(Stallaert, et al., 2011;</ref><ref type="bibr" target="#b10">Hermans, 2003)</ref>. Recent work investigating EP 2 receptor activation with butaprost, demonstrated not only the conventional Gα s -cAMP pathway activation but also Gα q/11 -calcium pathway activation upon ligand binding <ref type="bibr" target="#b12">(Kandola et al. , 2014)</ref>. Therefore, like forskolin and cholera toxin, which directly activate adenylate cyclase and thereby stimulate only the cAMP pathway, JV-GL1 may induce signal bias <ref type="bibr" target="#b45">(Wold et al., 2019)</ref> and signal primarily via the Gα s -cAMP pathway by virtue of a novel interaction with the EP 2 receptor. A study using cellular dielectric spectroscopy demonstrated that the EP 2 antagonist AH6809 could not completely block JV-GL1 at the EP 2 receptor, in human ciliary muscle cells <ref type="bibr" target="#b46">(Woodward, et al. , 2019a)</ref>. This finding suggests that JV-GL1 may be binding to a possible allosteric site on the EP 2 receptor where endogenous PGE 2 does not bind, or bind to the EP 2 receptor in a different way. Allosteric binding and a potential Gα s -cAMP pathway bias may be responsible for JV-GL1 long duration effects. This would set it apart from unbiased EP 2 agonists such as butaprost and merit further research into its mechanism of action.</p><p>The long duration of action of JV-GL1 may result from allosteric binding, thereby implying that the binding of other anti-glaucoma EP 2 agonists <ref type="bibr" target="#b47">(Woodward et al., 2019b)</ref> to their target receptor is orthosteric. The long duration of action on IOP and the inherent activity on human ciliary smooth muscle cells could be indicative of JV-GL1 as a positive allosteric modulator. One, and only one, possible published explanation <ref type="bibr" target="#b11">(Jiang et al., 2010)</ref> directly relevant to the ultra-long action of JV-GL1 on IOP involves allosteric modulation of the EP 2 receptor. More pertinent to the extended ocular hypotensive activity is that allosteric potentiation of EP 2 receptor activity is favoured by an ester moiety compared to a carboxylate 22 . The unexpected activity of JV-GL1 on ciliary smooth muscle cells correlates with manifestation of activity in intact cells rather than cell-free assays for EP 2 allosteric potentiators 22 . JV-GL1 would be an ideal compound for elucidating the crystal structure of the EP 2 and thereby gain valuable insights into orthosteric and allosteric binding sites and drug design.</p><p>In summary, the long-acting effects of JV-GL1 on IOP are EP 2 receptor mediated and this provides an intriguing avenue of future investigation with respect to mechanisms that impart such extended biological activities. Beyond the significant potential benefits of JV-GL1 for improved glaucoma treatment, there are also implications for pre-term labour, asthma, and the anti-inflammatory effects of EP 2 agonists. Future research may reveal similar advantages for compounds designed to be ultra-long acting at other GPCRs.</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Author contributions</head><p>Jacques A Bertrand, co-authored first draft of manuscript, performed all genetic/molecular biological studies, performed all intraocular pressure studies, and co-performed aqueous humor dynamics studies David F Woodward, co-authored first draft of manuscript, conceived and directed the research, co-invented JV-GL1, co-authored final version.</p><p>Joseph M Sherwood, Invented and co-performed iPerfusion studies, devised graphical presentation, codirected statistical analyses.</p><p>Jenny W Wang, co-invented JV-GL1 and provided samples of JV-GL1 and its free acid, co-authored second draft.</p><p>Robert A Coleman, provided expert advice on EP2 receptor pharmacology, co-authored second draft.</p><p>Darryl R Overby, s tudy director, co-directed data analysis and presentation, co-authored final version</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p>DF Woodward and JW Wang are inventors of a patent asssigned to the company that they founded, JeniVision.</p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Declaration of transparency and scientific rigour</head><p>This declaration acknowledges that this paper adheres to the priciples for transparent reporting and scientific rigour of pre-clinical research recommnded by funding agencies, publishers, and other organisations engaged in supporting research. IOP represents the difference in IOP between the treated eye relative to the contralateral untreated eye. B) Acute effect of 100 nM de-esterified JV-GL1 on outflow facility of enucleated C57BL/6J mouse eyes was not significantly different relative to contralateral vehicle perfused control eyes (-6% <ref type="bibr">[-22, 13]</ref>, P =0.4, n=5 pairs). Each data point shows the relative difference in reference facility C r , between paired eyes comparing the treated with respect to the untreated control eye. The error bars represent the 95% confidence intervals on the relative difference in C r . The light shaded region represents the best estimate of the sample distribution, with the geometric mean and two-sigma limits represented by the thick and thin horizontal white lines respectively. Dark central bands within the distribution represent the 95% CI on the estimated mean. <ref type="figure">Figure 2</ref>. A) Effect of JV-GL1 and butaprost on IOP of SI-OHT mice relative to the pre-treatment time point (δIOP). Single, bilateral topical applications of 0.01% JV-GL1 to SI-OHT C57BL/6J mice (first red arrow) reduced IOP by -2.3 [-3.4, -1.2] mmHg (P =0.01; n=9) after 3 hours and maintained significant suppression for up to 6 days (-2.8 [-3.7, -2.0]; P =0.001; n=9). Comparatively, 0.01% butaprost reduced IOP after 3 hours by -2.5 [-4.2, -1.0] mmHg, returning to pre-treatment levels by the following 2-day time point <ref type="bibr">(-0.8 [-1.5, 0</ref>.0] mmHg; P =0.6; n=9). A second unilateral topical application of 0.01% JV-GL1 (second red arrow) significantly reduced IOP of the treated eye by -2.3 [-3.4, -1.2] mmHg after 3 days, compared to contralateral vehicle treated eye (P =0.04, n=9). Error bars are 95% confidence intervals.B) 3 days after treatment with JV-GL1, outflow facility was not significantly altered (18% [-7%, 50%]; P=0.2, n=9 pairs) relative to vehicle treated eyes of SI-OHT C57BL/6J mice. Each data point shows the relative difference in reference facility, C r , between paired eyes comparing the treated with respect to the untreated control eye. The error bars represent the 95% confidence intervals on the relative difference in C r . The light shaded region represents the best estimate of the sample distribution, with the geometric mean and two-sigma limits represented by the thick and thin horizontal white lines respectively. Dark central bands within the distribution represent the 95% CI on the estimated mean.  </p></div>
      <div xmlns="http://www.tei-c.org/ns/1.0"><head>Figures and Legends</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>Like JV-GL1, butaprost lowered IOP in the Ptger2 +/+ mice at 3 hrs relative to the contralateral vehicle-treated eye ([?]IOP = -2.4 [-4.2, -0.6] mmHg; P &lt;0.01; n=7), but butaprost did not affect IOP in the Ptger2 -/- littermates ([?]IOP = 0.4 [-0.7,</figDesc></figure>
      <figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc>week, while IOP remained near baseline in the group receiving unloaded nanoparticles ([?]IOP = 0.0 [-1.6, 1.6] mmHg; Supplemental Figure 3). In the hypertensives, a single topical drop of JV-GL1 given unilaterally (10 l, 0.01%) reduced IOP after 3 hrs by 3.1 [-4.4, -1.8] mmHg (P =0.01, n=8; Fig. 3). The IOP reduction in hypertensives persisted for up to 4 days ([?]IOP = -2.8 [-3.8, -1.8] mmHg,P =0.04), but had returned to pre-treatment levels by 6 days ([?]IOP = -1.4 [-2.9, 0.2] mmHg, P =0.5).</figDesc></figure>
      <figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 1 .</head><label>1</label><figDesc>A) Effect of JV-GL1 and butaprost in normotensive Ptger2 +/+ and Ptger2 -/-mice. Three hours after single topical applications of 0.01% JV-GL1 or 0.01% butaprost to Ptger2 +/+ mice, IOP decreased to -3.1 [-4.1, -2.1] mmHg and -2.4 [-4.2, -0.6] mmHg respectively, returning to -0.002 [-1.0, 1.0] mmHg and 0.6 [-0.5, 1.5] mmHg by 24 hours. No effect was observed in Ptger2 -/-mice after 3 hours (0.8 [-0.4, 2.0] mmHg vs 0.4 [-0.7, 1.5] mmHg, for JV-GL1 and butaprost respectively. Error bars are 95% confidence intervals.</figDesc></figure>
      <figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc>JV-GL1 decreases IOP in steroid treated ocular hypertensive mice after 3 hours, when IOP = -3.1 [-4.4, -1.8] mmHg (P =0.01; n=8), with significant effects persisting for 4 days (IOP = -2.8 [-3.8, -1.8] mmHg; P =0.04; n=8). In contrast, JV-GL1 decreases IOP in normotensive littermates at the 3 hour time point only (IOP = -1.6 [-2.7, -0.5] mmHg; P =0.008; n=9). Red arrow indicates dosage time point and error bars are 95% confidence intervals.</figDesc></figure>
      <figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4 .</head><label>4</label><figDesc>JV-GL1 decreases IOP in steroid induced ocular hypertensive Ptger2 +/+ mice after 3 hours, when IOP = -4.2[-5.6, -2.9] mmHg (P &lt;0.0001; n=10), with significant effects persisting for 4 days (IOP = -2.6 [-3.3, -1.8] mmHg (P =0.02; n=10). JV-GL1 does not significantly affect IOP in steroid induced ocular hypertensivePtger2 -/-mice. Red arrow indicates dosage time point and error bars are 95% confidence intervals.ReferencesAgrahari V, Li G, Agrahali V, Navarro I Perkumas K,<ref type="bibr" target="#b0">Mandal A, et al.(2017)</ref> 'Pentablock copolymer dex- amethasone nanoformulations elevate MYOC : in vitro liberation , activity and safety in human trabecular meshwork cells. Nanomed(London) 12: 1911-1926 doi: 10.2217-0140.   Boland MV, Chang DS, Frazier T, Plyler R, Friedman DS (2014 Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study.JAMA Ophthalmol 132: 838-844.11Posted on Authorea 27 Mar 2020 -CC BY 4.0 -https://doi.org/10.22541/au.158531795.54392142 -This a preprint and has not been peer reviewed. Data may be preliminary.<ref type="bibr" target="#b2">Caprioli J, Sears M, Bausher L, Gregory D, Mead A (1984)</ref> Forskolin lowers intraocular pressure by reducing aqueous inflow',Investigative Ophthalmology and Visual Science , 25: 268-276. Coleman RA, Woodrooffe AJ, Clark KL, Toris CB, Fan S, Wang J, Woodward DF (2018) 'The affinity, intrin- sic activity and selectivity of a structurally novel prostaglandin EP 2 receptor agonist at human prostanoid receptors', British Journal of Pharmacology . doi: 10.1111/bph.14525. el-Shabrawi Y, Eckhardt M, Berghold A, Faulborn J, Auboeck L, Mangge H, Ardjomand N (2000) 'Syn- thesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cul- tures after treatment with latanoprost and dexamethasone.', Eye (London, England) 14: 375-383. doi: 10.1038/eye.2000.92. Forster C, Kahles T, Kietz S, Drenckhahn D (2007) 'Dexamethasone induces the expression of metallo- proteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND.', The Journal of physiology 580: 937-949. doi: 10.1113/jphysiol.2007.129007. Fuwa M, Toris CB, Fan S, Taniguchi T, Ichikawa M, Odani-Kawabata Net al. (2018) 'Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys', Journal of Ocular Pharmacology and Therapeutics 34: 531-537. doi: 10.1089/jop.2017.0146. Gerritsen ME, Weinstein BI, Gordon GG, Southren AL (1986) 'Prostaglandin synthesis and release from cultured human trabecular-meshwork cells and scleral fibroblasts.', Experimental eye research .43:1089-1102.Gregory D, Sears M, Bausher L, Mishima H, Mead A (1981) 'Intraocular pressure and aqueous flow are decreased by cholera toxin.',Investigative ophthalmology &amp; visual science . 20: 371-381. Hacker, M. C. and Mikos, A. G. (2011) 'Chapter 33 -Synthetic Polymers', in Atala, A. et al. (eds). San Diego: Academic Press, pp. 587-622. doi: https://doi.org/10.1016/B978-0-12-381422-7.10033-1. Hermans, E. (2003) 'Biochemical and pharmacological control of the multiplicity of coupling at G-protein- coupled receptors.Pharmacology and Therapeutics , 99: 25-44. doi: 10.1016/S0163-7258(03)00051-2. . Jiang J, Ganesh T, Du Y, Thepchatri P, Rojas A, Lewis I et al. (2010), Neuroprotection by selec- tive allosteric potentiators of the EP2 prostaglandin receptor. Proc Nat Acad Sci 107: 2307-2312. doi: 10.1073/pnas.1120195109. Kandola MK, Sykes L, Lee YS, Johnson MR, Hanyaloglu AC, Bennett PR (2014) 'EP2 receptor activates dual g protein signaling pathways that mediate contrasting proinflammatory and relaxatory responses in term pregnant human myometrium', Endocrinology , 155: 605-617. doi: 10.1210/en.2013-1761. Kennedy CR Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, et al.(1999) 'Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor.', Nature medicine . United States, 5(2), pp. 217-220. doi: 10.1038/5583. Kilkenny C, Browne W. Cuthill IC, Emerson M, Altma DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. British Journal of Pharmacology 160: 1577-1579 doi: 10.4103/0976- 500X.72351 Ko, MK, Tan, JCH (2013) 'Contractile markers distinguish structures of the mouse aqueous drainage tract', Molecular Vision 19: 2561-2570. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867161/. Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ (2019) Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev doi: 10.1002/14651858 CDO12930. Matrisian LM (1990) 'Metalloproteinases and their inhibitors in matrix remodeling', Trends in Genetics . Elsevier, 6, pp. 121-125. doi: 10.1016/0168-9525(90)90126-Q.12 Posted on Authorea 27 Mar 2020 -CC BY 4.0 -https://doi.org/10.22541/au.158531795.54392142 -This a preprint and has not been peer reviewed. Data may be preliminary. McCall RL, Sirianni RW (2013) 'PLGA Nanoparticles Formed by Single-or Double-emulsion with Vitamin E-TPGS', Journal of Visualized Experiments , (82), pp. 1-8. doi: 10.3791/51015. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. British Journal Pharmacology 172: 3189-3193. doi: 10.1111/bph.12955. MV, Boland Chang DS, Frazier T, Plyler R, Friedman DS (2014) 'Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: The automated dosing reminder study',JAMA Ophthalmology , 132: 838-844. http://dx.doi.org/10.1001/jamaophthalmol.2014.856. Nilsson SFE Drecoll E, Lütjen-Drecoll E, Toris CB, Krauss AH, Kharlamb Aet al. (2006) 'The prostano- id EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey',Investigative Ophthalmology and Visual Science , 47: 4042-4049. doi: 10.1167/iovs.05-1627.Ocklind, A. (1998) 'Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections.',Experimental eye research 67: 179-191. doi: 10.1006/exer.1998.0508. Okeke CO Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Friedman DSet al. (2009) 'Adherence with Topical Glaucoma Medication Monitored Electronically. The Travatan Dosing Aid Study',Ophthalmology 116: 191-199. doi: 10.1016/j.ophtha.2008.09.004. Overby DR Bertrand J, Tektas OY, Boussommier-Calleja A, Schicht M, Ethier CR et al. (2014) 'Ultrastruc- tural changes associated with dexamethasone-induced ocular hypertension in mice', Investigative Ophthal- mology and Visual Science , 55(8), pp. 4922-4933. doi: 10.1167/iovs.14-14429. Pierce KL Gil DW, Woodward DF, Regan JW (1995) 'Cloning of human prostanoid receptors.', Trends in pharmacological sciences . England, 16(8), pp. 253-256. Prasanna G, Carreiro S, Anderson S, Gukasyan H, Sartnurak S, Younis H,et al. (2011) 'Effect of PF-04217329 a prodrug of a selective prostaglandin EP 2 agonist on intraocular pressure in preclinical models of glaucoma', Experimental Eye Research . Elsevier Ltd, 93(3), pp. 256-264. doi: 10.1016/j.exer.2011.02.015. Raghunathan VK, Morgan JT, Park SA, Weber D, Phinney BS, Murphy CJet al. (2015) 'Dexamethasone Stiffens Trabecular Meshwork, Trabecular Meshwork Cells, and Matrix.', Investigative ophthalmology &amp; visual science . 56: 4447-4459. doi: 10.1167/iovs.15-16739. Regan JW, Bailey TJ, Pepperl DJ, Pierce KL, Bogardus AM, Donello JE,et al. (1994) 'Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype.',Molecular pharmacology , 46: 213-220. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. World Health Organ Bulletin 82: 844-851.Pdf', 012831(04). doi: /S0042-96862004001100009. Saeki T,.Ota T, Aihara M, Araie M et al. (2009) 'Effects of prostanoid ep agonists on mouse intraocular pressure',Investigative Ophthalmology and Visual Science , 50: 2201-2208. doi: 10.1167/iovs.08-2800. Sakurai M, Nakamura K, Miura K, Yoshita K, Takamura T, Nagasawa SYet al. (2014) 'Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension', British Journal of Ophthalmology , 98(4), pp. 469-473. doi: 10.1136/bjophthalmol-2013-304267. Sambhara D, Aref AA (2014) 'Glaucoma management: Relative value and place in therapy of available drug treatments', Therapeutic Advances in Chronic Disease , 5: 30-43. doi: 10.1177/2040622313511286. Schachtschabel U, Lindsey JD.Weinreb RN (2000) 'The mechanism of action of prostaglandins on uveoscleral outflow', Current Opinion in Ophthalmology , 11: 112-115. https://journals.lww.com/co- ophthalmology/Fulltext/2000/04000/The mechanism of action of prostaglandins on.8.aspx. 13 Posted on Authorea 27 Mar 2020 -CC BY 4.0 -https://doi.org/10.22541/au.158531795.54392142 -This a preprint and has not been peer reviewed. Data may be preliminary. Scherer WJ (2002) 'A retrospective review of non-responders to latanoprost.'Journal of ocular pharmacology and therapeutics 18: 287-291. doi: 10.1089/108076802760116205. Schneider CA, Rasband WS, Eliceiri KW (2012) 'NIH Image to ImageJ: 25 years of image analysis', Nature methods , 9: 671-675.https://www.ncbi.nlm.nih.gov/pubmed/22930834. Sherwood JM, Reina-Torres E, Bertrand JA, Rowe B, Overby DR (2016) 'Measurement of Outflow Facility Using iPerfusion.', PloS one . United States, 11(3), p. e0150694. doi: 10.1371/journal.pone.0150694. Shim MS, Kim KY, Ju, WK (2017) 'Role of cyclic AMP in the eye with glaucoma', BMB Reports , 50: 60-70. doi: 10.5483/BMBRep.2017.50.2.200. Sleath B, Blalock SJ, Covert D, Skinner AC, Muir KW, Robin AL (2012) 'NIH Public Access', Opthalmology , 118(12), pp. 2398-2402. doi: 10.1016/j.ophtha.2011.05.013.The. Stallaert W, Christopoulos A, Bouvier M (2011) 'Ligand functional selectivity and quantitative phar- macology at G protein-coupled receptors', Expert Opinion on Drug Discovery , 6: 811-825. doi: 10.1517/17460441.2011.586691. Tamboli V, Mishra GP, Mitra AK (2013) 'Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA)-based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles', Colloid and Polymer Science , 291: 1235-1245. doi: 10.1007/s00396-012-2854-0. Tamm ER, Lutjen-Drecoll E (1996) 'Ciliary body.', Microscopy research and technique . 33: 390-439. doi: 10.1002/(SICI)1097-0029(19960401)33:5&lt;390::AID-JEMT2&gt;3.0.CO;2-S. Wang K, Li G, Read AT, Navarro I, Mitra AK, Stamer WD (2018) 'The relationship between outflow resistance and trabecular meshwork stiffness in mice. Scientific Reports 8:1-12. doi: 10.1038/s41598-018- 24165-w. Wendell SG, Fan H, Zhang C (2020) G protein coupled receptors in asthma therapy: pharmacology and drug action. Pharmacological Reviews 72: 1-49. doi: 10.1124/pr.118.016899 WinklerNS, Fautsch MP (2014) 'Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways', Journal of Ocular Pharmacology and Therapeutics , 30: 102-109. doi: 10.1089/jop.2013.0179. Wold EA, Chen J, Cunningham KA, Zhou J (2019) Allosteric modulation of class A GPCRs: Targets, Agents, and Emerging Concepts. Journal of Medicinal Chemistry 62: 88-127. doi: 10.1021/acs.jmedchem.8b00875. Woodward, DF, Wang JW, Coleman RA, et al. (2019a) 'A Highly Effective and Ultra-Long-Acting Anti- Glaucoma Drug, with a Novel Periorbital Delivery Method.', Journal of ocular pharmacology and therapeutics 35:265-277.doi: 10.1089/jop.2018.0126. Woodward DF, Wang J W, Stamer WD, Wang JW, Stamer WD, Lütjen-Drecoll E, Krauss AH, Toris CB (2019b) 'Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere', Journal of Ocular Pharmacology and Therapeutics35:469-474 doi: 10.1089/jop.2019.0041. Xu J, Kim GM, Ahmed SH, Xu J , Yan P, Xu XM, Hsu CY (2001) 'Glucocorticoid receptor-mediated sup- pression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury.The Journal of neuroscience 21: 92-97. Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, et al. (2013) 'Highly penetrative, drug- loaded nanocarriers improve treatment of glioblastoma', Proceedings of the National Academy of Sciences of the United States of America . 110: 11751-11756. doi: 10.1073/pnas.1304504110. 14 Posted on Authorea 27 Mar 2020 -CC BY 4.0 -https://doi.org/10.22541/au.158531795.54392142 -This a preprint and has not been peer reviewed. Data may be preliminary. Supplemental Figure 1: IOP (A) and outflow facility(B) in Ptger2 +/+ mice andPtger2 -/-littermates. (C) Table of values. (D) Representative genotyping result fromPtger2 -/-(300 base pairs) and litter- matePtger2 +/+ mice (165 base pairs), ladder is 1 kb. The presentation of data in panels A and B is as described in Figures 1 and 2 of the main text. Supplemental Figure 2: (A) IOP elevation in response to dexamethasone loaded nanoparticles. (B)Body weight of the mice was unaffected by the steroids, increasing from a mean of25.7 [25, 26]  grams to 27.9[27, 29]  grams over the duration of the study. The presentation of data in panels A and B is as described inFigures 1 and 2of the main text, with grey lines connecting paired data at different time points.15 Posted on Authorea 27 Mar 2020 -CC BY 4.0 -https://doi.org/10.22541/au.158531795.54392142 -This a preprint and has not been peer reviewed. Data may be preliminary. Supplemental Figure 3: (A) IOP elevation in response to either dexamethasone loaded or unloaded nanoparticles in C57BL/6J mice. (B) Body weight of the mice was unaffected by the steroids. The pre- sentation of data in panels A and B is as described in Figures 1 and 2 of the main text, with grey lines connecting paired data at different time points.</figDesc></figure>
      <note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Posted on Authorea 27 Mar 2020 -CC BY 4.0 -https://doi.org/10.22541/au.158531795.54392142 -This a preprint and has not been peer reviewed. Data may be preliminary.</note>
    </body>
    <back>
      <div type="references">

        <listBibl>

          <biblStruct xml:id="b0">
            <analytic>
              <title level="a" type="main">Pentablock copolymer dexamethasone nanoformulations elevate MYOC: in vitro liberation, activity and safety in human trabecular meshwork cells</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vibhuti</forename><surname>Agrahari</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guorong</forename><surname>Li</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vivek</forename><surname>Agrahari</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Iris</forename><surname>Navarro</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kristin</forename><surname>Perkumas</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Abhirup</forename><surname>Mandal</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">Daniel</forename><surname>Stamer</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ashim</forename><forename type="middle">K</forename><surname>Mitra</surname></persName>
              </author>
              <idno type="doi">10.2217/nnm-2017-0140</idno>
              <idno>doi: 10.2217-0140</idno>
            </analytic>
            <monogr>
              <title level="j">Nanomedicine</title>
              <title level="j" type="abbrev">Nanomedicine</title>
              <idno type="ISSN">1743-5889</idno>
              <idno type="ISSNe">1748-6963</idno>
              <imprint>
                <biblScope unit="volume">12</biblScope>
                <biblScope unit="issue">16</biblScope>
                <biblScope unit="page" from="1911" to="1926" />
                <date type="published" when="2017-08" />
                <publisher>Future Medicine Ltd</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b1">
            <analytic>
              <title level="a" type="main">Electronic Monitoring to Assess Adherence With Once-Daily Glaucoma Medications and Risk Factors for Nonadherence</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">V</forename><surname>Boland</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dolly</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Travis</forename><surname>Frazier</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryan</forename><surname>Plyler</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">S</forename><surname>Friedman</surname></persName>
              </author>
              <idno type="doi">10.1001/jamaophthalmol.2014.856</idno>
            </analytic>
            <monogr>
              <title level="j">JAMA Ophthalmology</title>
              <title level="j" type="abbrev">JAMA Ophthalmol</title>
              <idno type="ISSN">2168-6165</idno>
              <imprint>
                <biblScope unit="volume">132</biblScope>
                <biblScope unit="issue">7</biblScope>
                <biblScope unit="page">838</biblScope>
                <date type="published" when="2014-07-01" />
                <publisher>American Medical Association (AMA)</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b2">
            <analytic>
              <title level="a" type="main">Forskolin lowers intraocular pressure by reducing aqueous inflow</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Caprioli</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Sears</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bausher</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Gregory</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Mead</surname></persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Investigative Ophthalmology and Visual Science</title>
              <imprint>
                <biblScope unit="volume">25</biblScope>
                <biblScope unit="page" from="268" to="276" />
                <date type="published" when="1984" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b3">
            <analytic>
              <title level="a" type="main">The affinity, intrinsic activity and selectivity of a structurally novel EP 2 receptor agonist at human prostanoid receptors</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Coleman</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Woodrooffe</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Clark</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">B</forename><surname>Toris</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Fan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Wang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">F</forename><surname>Woodward</surname></persName>
              </author>
              <idno type="doi">10.1111/bph.14525</idno>
            </analytic>
            <monogr>
              <title level="j">British Journal of Pharmacology</title>
              <title level="j" type="abbrev">British Journal of Pharmacology</title>
              <idno type="ISSN">0007-1188</idno>
              <idno type="ISSNe">1476-5381</idno>
              <imprint>
                <biblScope unit="volume">176</biblScope>
                <biblScope unit="issue">5</biblScope>
                <biblScope unit="page" from="687" to="698" />
                <date type="published" when="2019-03" />
                <publisher>Wiley</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b4">
            <analytic>
              <title level="a" type="main">Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yosuf</forename><surname>El-Shabrawi</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Eckhardt</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrea</forename><surname>Berghold</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jürgen</forename><surname>Faulborn</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ludwig</forename><surname>Auboeck</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harald</forename><surname>Mangge</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Navid</forename><surname>Ardjomand</surname></persName>
              </author>
              <idno type="doi">10.1038/eye.2000.92</idno>
            </analytic>
            <monogr>
              <title level="j">Eye</title>
              <title level="j" type="abbrev">Eye</title>
              <idno type="ISSN">0950-222X</idno>
              <idno type="ISSNe">1476-5454</idno>
              <imprint>
                <biblScope unit="volume">14</biblScope>
                <biblScope unit="issue">3</biblScope>
                <biblScope unit="page" from="375" to="383" />
                <date type="published" when="2000-05" />
                <publisher>Springer Science and Business Media LLC</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b5">
            <analytic>
              <title level="a" type="main">Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carola</forename><surname>Förster</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Timo</forename><surname>Kahles</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Silke</forename><surname>Kietz</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Detlev</forename><surname>Drenckhahn</surname></persName>
              </author>
              <idno type="doi">10.1113/jphysiol.2007.129007</idno>
            </analytic>
            <monogr>
              <title level="j">The Journal of Physiology</title>
              <idno type="ISSN">0022-3751</idno>
              <imprint>
                <biblScope unit="volume">580</biblScope>
                <biblScope unit="issue">3</biblScope>
                <biblScope unit="page" from="937" to="949" />
                <date type="published" when="2007-05-01" />
                <publisher>Wiley</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b6">
            <analytic>
              <title level="a" type="main">Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masahiro</forename><surname>Fuwa</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carol</forename><forename type="middle">B</forename><surname>Toris</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shan</forename><surname>Fan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takazumi</forename><surname>Taniguchi</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masaki</forename><surname>Ichikawa</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noriko</forename><surname>Odani-Kawabata</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryo</forename><surname>Iwamura</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenji</forename><surname>Yoneda</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takeshi</forename><surname>Matsugi</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Naveed</forename><forename type="middle">K</forename><surname>Shams</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin-Zhong</forename><surname>Zhang</surname></persName>
              </author>
              <idno type="doi">10.1089/jop.2017.0146</idno>
            </analytic>
            <monogr>
              <title level="j">Journal of Ocular Pharmacology and Therapeutics</title>
              <title level="j" type="abbrev">Journal of Ocular Pharmacology and Therapeutics</title>
              <idno type="ISSN">1080-7683</idno>
              <idno type="ISSNe">1557-7732</idno>
              <imprint>
                <biblScope unit="volume">34</biblScope>
                <biblScope unit="issue">7</biblScope>
                <biblScope unit="page" from="531" to="537" />
                <date type="published" when="2018-09" />
                <publisher>Mary Ann Liebert Inc</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b7">
            <analytic>
              <title level="a" type="main">Prostaglandin synthesis and release from cultured human trabecular-meshwork cells and scleral fibroblasts</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mary</forename><forename type="middle">E</forename><surname>Gerritsen</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bernard</forename><forename type="middle">I</forename><surname>Weinstein</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gary</forename><forename type="middle">G</forename><surname>Gordon</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">Louis</forename><surname>Southren</surname></persName>
              </author>
              <idno type="doi">10.1016/0014-4835(86)90085-0</idno>
            </analytic>
            <monogr>
              <title level="j">Experimental Eye Research</title>
              <title level="j" type="abbrev">Experimental Eye Research</title>
              <idno type="ISSN">0014-4835</idno>
              <imprint>
                <biblScope unit="volume">43</biblScope>
                <biblScope unit="issue">6</biblScope>
                <biblScope unit="page" from="1089" to="1102" />
                <date type="published" when="1986-12" />
                <publisher>Elsevier BV</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b8">
            <analytic>
              <title level="a" type="main">Intraocular pressure and aqueous flow are decreased by cholera toxin</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Gregory</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Sears</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bausher</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Mishima</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Mead</surname></persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Investigative ophthalmology &amp; visual science</title>
              <imprint>
                <biblScope unit="volume">20</biblScope>
                <biblScope unit="page" from="371" to="381" />
                <date type="published" when="1981" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b9">
            <monogr>
              <title level="m" type="main">Chapter 33 -Synthetic Polymers</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Hacker</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">G</forename><surname>Mikos</surname></persName>
              </author>
              <idno type="doi">10.1016/B978-0-12-381422-7.10033-1</idno>
              <ptr target="https://doi.org/10.1016/B978-0-12-381422-7.10033-1" />
              <editor>Atala, A. et al.</editor>
              <imprint>
                <date type="published" when="2011" />
                <publisher>Academic Press</publisher>
                <biblScope unit="page" from="587" to="622" />
                <pubPlace>San Diego</pubPlace>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b10">
            <analytic>
              <title level="a" type="main">Biochemical and pharmacological control of the multiplicity of coupling at G-proteincoupled receptors</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Hermans</surname></persName>
              </author>
              <idno type="doi">doi:10.1016/S0163-7258(03)00051-2.</idno>
            </analytic>
            <monogr>
              <title level="j">Pharmacology and Therapeutics</title>
              <imprint>
                <biblScope unit="volume">99</biblScope>
                <biblScope unit="page" from="25" to="44" />
                <date type="published" when="2003" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b11">
            <analytic>
              <title level="a" type="main">Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Jiang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ganesh</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Du</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Thepchatri</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Rojas</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Lewis</surname></persName>
              </author>
              <idno type="doi">doi:10.1073/pnas.1120195109</idno>
            </analytic>
            <monogr>
              <title level="j">Proc Nat Acad Sci</title>
              <imprint>
                <biblScope unit="volume">107</biblScope>
                <biblScope unit="page" from="2307" to="2312" />
                <date type="published" when="2010" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b12">
            <analytic>
              <title level="a" type="main">EP2 Receptor Activates Dual G Protein Signaling Pathways that Mediate Contrasting Proinflammatory and Relaxatory Responses in Term Pregnant Human Myometrium</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mandeep</forename><forename type="middle">K</forename><surname>Kandola</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lynne</forename><surname>Sykes</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yun</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aylin</forename><forename type="middle">C</forename><surname>Hanyaloglu</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Phillip</forename><forename type="middle">R</forename><surname>Bennett</surname></persName>
              </author>
              <idno type="doi">10.1210/en.2013-1761</idno>
            </analytic>
            <monogr>
              <title level="j">Endocrinology</title>
              <title level="j" type="abbrev">Endocrinology</title>
              <idno type="ISSN">0013-7227</idno>
              <idno type="ISSNe">1945-7170</idno>
              <imprint>
                <biblScope unit="volume">155</biblScope>
                <biblScope unit="issue">2</biblScope>
                <biblScope unit="page" from="605" to="617" />
                <date type="published" when="2014-02" />
                <publisher>The Endocrine Society</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b13">
            <analytic>
              <title level="a" type="main">Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Kennedy Cr Zhang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Brandon</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Guan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Coffee</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">D</forename><surname>Funk</surname></persName>
              </author>
              <idno type="doi">doi:10.1038/5583</idno>
            </analytic>
            <monogr>
              <title level="j">Nature medicine . United States</title>
              <imprint>
                <biblScope unit="volume">5</biblScope>
                <biblScope unit="issue">2</biblScope>
                <biblScope unit="page" from="217" to="220" />
                <date type="published" when="1999" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b14">
            <analytic>
              <title level="a" type="main">Animal research: reporting in vivo experiments: the ARRIVE guidelines</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Kilkenny</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Browne</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">C</forename><surname>Cuthill</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Emerson</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">G</forename><surname>Altma</surname></persName>
              </author>
              <idno type="doi">doi:10.4103/0976-500X.72351</idno>
            </analytic>
            <monogr>
              <title level="j">British Journal of Pharmacology</title>
              <imprint>
                <biblScope unit="volume">160</biblScope>
                <biblScope unit="page" from="1577" to="1579" />
                <date type="published" when="2010" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b15">
            <analytic>
              <title level="a" type="main">Contractile markers distinguish structures of the mouse aqueous drainage tract</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">K</forename><surname>Ko</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Tan</surname></persName>
              </author>
              <ptr target="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867161/" />
            </analytic>
            <monogr>
              <title level="j">Molecular Vision</title>
              <imprint>
                <biblScope unit="volume">19</biblScope>
                <biblScope unit="page" from="2561" to="2570" />
                <date type="published" when="2013" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b16">
            <analytic>
              <title level="a" type="main">Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Maqsood</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">N</forename><surname>Ho</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Palmer</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">J</forename><surname>Eccles</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Munavvar</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Wang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Crossingham</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Evans</surname></persName>
              </author>
              <idno type="doi">doi:10.1002/14651858CDO12930</idno>
            </analytic>
            <monogr>
              <title level="j">Cochrane Database Syst Rev</title>
              <imprint>
                <date type="published" when="2019" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b17">
            <analytic>
              <title level="a" type="main">Metalloproteinases and their inhibitors in matrix remodeling</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Matrisian</surname></persName>
              </author>
              <idno type="doi">10.1016/0168-9525(90)90126-q</idno>
            </analytic>
            <monogr>
              <title level="j">Trends in Genetics</title>
              <title level="j" type="abbrev">Trends in Genetics</title>
              <idno type="ISSN">0168-9525</idno>
              <imprint>
                <biblScope unit="volume">6</biblScope>
                <biblScope unit="page" from="121" to="125" />
                <date type="published" when="1990" />
                <publisher>Elsevier BV</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b18">
            <analytic>
              <title level="a" type="main">PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rebecca</forename><forename type="middle">L</forename><surname>Mccall</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rachael</forename><forename type="middle">W</forename><surname>Sirianni</surname></persName>
              </author>
              <idno type="doi">10.3791/51015</idno>
            </analytic>
            <monogr>
              <title level="j">Journal of Visualized Experiments</title>
              <title level="j" type="abbrev">JoVE</title>
              <idno type="ISSNe">1940-087X</idno>
              <imprint>
                <biblScope unit="issue">82</biblScope>
                <biblScope unit="page" from="1" to="8" />
                <date type="published" when="2013" />
                <publisher>MyJove Corporation</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b19">
            <analytic>
              <title level="a" type="main">Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">C</forename><surname>Mcgrath</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elliot</forename><surname>Lilley</surname></persName>
              </author>
              <idno type="doi">10.1111/bph.12955</idno>
            </analytic>
            <monogr>
              <title level="j">British Journal of Pharmacology</title>
              <title level="j" type="abbrev">Br J Pharmacol</title>
              <idno type="ISSN">0007-1188</idno>
              <imprint>
                <biblScope unit="volume">172</biblScope>
                <biblScope unit="issue">13</biblScope>
                <biblScope unit="page" from="3189" to="3193" />
                <date type="published" when="2015-07" />
                <publisher>Wiley</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b20">
            <analytic>
              <title level="a" type="main">Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: The automated dosing reminder study</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Boland</forename><surname>Mv</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Frazier</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Plyler</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Friedman</surname></persName>
              </author>
              <idno type="doi">10.1001/jamaophthalmol.2014.856</idno>
              <ptr target="http://dx.doi.org/10.1001/jamaophthalmol.2014.856" />
            </analytic>
            <monogr>
              <title level="j">JAMA Ophthalmology</title>
              <imprint>
                <biblScope unit="volume">132</biblScope>
                <biblScope unit="page" from="838" to="844" />
                <date type="published" when="2014" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b21">
            <analytic>
              <title level="a" type="main">The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Nilsson Sfe Drecoll</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Lütjen-Drecoll</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">B</forename><surname>Toris</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Krauss</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Kharlamb</surname></persName>
              </author>
              <idno type="doi">doi:10.1167/iovs.05-1627</idno>
            </analytic>
            <monogr>
              <title level="j">Investigative Ophthalmology and Visual Science</title>
              <imprint>
                <biblScope unit="volume">47</biblScope>
                <biblScope unit="page" from="4042" to="4049" />
                <date type="published" when="2006" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b22">
            <analytic>
              <title level="a" type="main">Effect of Latanoprost on the Extracellular Matrix of the Ciliary Muscle. A Study on Cultured Cells and Tissue Sections</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ocklind</surname></persName>
              </author>
              <idno type="doi">10.1006/exer.1998.0508</idno>
            </analytic>
            <monogr>
              <title level="j">Experimental Eye Research</title>
              <title level="j" type="abbrev">Experimental Eye Research</title>
              <idno type="ISSN">0014-4835</idno>
              <imprint>
                <biblScope unit="volume">67</biblScope>
                <biblScope unit="issue">2</biblScope>
                <biblScope unit="page" from="179" to="191" />
                <date type="published" when="1998-08" />
                <publisher>Elsevier BV</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b23">
            <analytic>
              <title level="a" type="main">Adherence with Topical Glaucoma Medication Monitored Electronically. The Travatan Dosing Aid Study</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Okeke</forename><surname>Co Quigley</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">A</forename><surname>Jampel</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">D</forename><surname>Ying</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Plyler</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Jiang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Friedman</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename></persName>
              </author>
              <idno type="doi">doi:10.1016/j.ophtha.2008.09.004</idno>
            </analytic>
            <monogr>
              <title level="j">Ophthalmology</title>
              <imprint>
                <biblScope unit="volume">116</biblScope>
                <biblScope unit="page" from="191" to="199" />
                <date type="published" when="2009" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b24">
            <monogr>
              <title level="m" type="main">Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice&apos;, Investigative Ophthalmology and Visual Science</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Overby</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bertrand</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">Y</forename><surname>Tektas</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Boussommier-Calleja</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Schicht</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">R</forename><surname>Ethier</surname></persName>
              </author>
              <idno type="doi">doi:10.1167/iovs.14-14429</idno>
              <imprint>
                <date type="published" when="2014" />
                <biblScope unit="volume">55</biblScope>
                <biblScope unit="page" from="4922" to="4933" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b25">
            <analytic>
              <title level="a" type="main">Cloning of human prostanoid receptors</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kristen</forename><forename type="middle">L</forename><surname>Pierce</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><forename type="middle">W</forename><surname>Gil</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">F</forename><surname>Woodward</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">W</forename><surname>Regan</surname></persName>
              </author>
              <idno type="doi">10.1016/s0165-6147(00)89035-5</idno>
            </analytic>
            <monogr>
              <title level="j">Trends in Pharmacological Sciences</title>
              <title level="j" type="abbrev">Trends in Pharmacological Sciences</title>
              <idno type="ISSN">0165-6147</idno>
              <imprint>
                <biblScope unit="volume">16</biblScope>
                <biblScope unit="issue">8</biblScope>
                <biblScope unit="page" from="253" to="256" />
                <date type="published" when="1995-08" />
                <publisher>Elsevier BV</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b26">
            <analytic>
              <title level="a" type="main">Effect of PF-04217329 a prodrug of a selective prostaglandin EP2 agonist on intraocular pressure in preclinical models of glaucoma</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ganesh</forename><surname>Prasanna</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Samantha</forename><surname>Carreiro</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Scott</forename><surname>Anderson</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hovhannes</forename><surname>Gukasyan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Soisurin</forename><surname>Sartnurak</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Husam</forename><surname>Younis</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Gale</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cathie</forename><surname>Xiang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><surname>Wells</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dac</forename><surname>Dinh</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chau</forename><surname>Almaden</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jay</forename><surname>Fortner</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carol</forename><surname>Toris</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Niesman</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><surname>Lafontaine</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Achim</forename><surname>Krauss</surname></persName>
              </author>
              <idno type="doi">10.1016/j.exer.2011.02.015</idno>
            </analytic>
            <monogr>
              <title level="j">Experimental Eye Research</title>
              <title level="j" type="abbrev">Experimental Eye Research</title>
              <idno type="ISSN">0014-4835</idno>
              <imprint>
                <biblScope unit="volume">93</biblScope>
                <biblScope unit="issue">3</biblScope>
                <biblScope unit="page" from="256" to="264" />
                <date type="published" when="2011-09" />
                <publisher>Elsevier BV</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b27">
            <monogr>
              <title level="m" type="main">Dexamethasone Stiffens Trabecular Meshwork, Trabecular Meshwork Cells, and Matrix.&apos;, Investigative ophthalmology &amp; visual science</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">K</forename><surname>Raghunathan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">T</forename><surname>Morgan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Park</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Weber</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">S</forename><surname>Phinney</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Murphy</surname></persName>
              </author>
              <idno type="doi">doi:10.1167/iovs.15-16739</idno>
              <imprint>
                <date type="published" when="2015" />
                <biblScope unit="volume">56</biblScope>
                <biblScope unit="page" from="4447" to="4459" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b28">
            <analytic>
              <title level="a" type="main">Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Regan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Bailey</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Pepperl</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Pierce</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Bogardus</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Donello</surname></persName>
              </author>
            </analytic>
            <monogr>
              <title level="m">Molecular pharmacology</title>
              <imprint>
                <date type="published" when="1994" />
                <biblScope unit="volume">46</biblScope>
                <biblScope unit="page" from="213" to="220" />
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b29">
            <analytic>
              <title level="a" type="main">Global data on visual impairment in the year 2002</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Resnikoff</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Pascolini</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Etya&amp;apos;ale</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Kocur</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Pararajasegaram</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">P</forename><surname>Pokharel</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">P</forename><surname>Mariotti</surname></persName>
              </author>
              <idno>doi: /S0042-96862004001100009</idno>
            </analytic>
            <monogr>
              <title level="j">World Health Organ Bulletin</title>
              <imprint>
                <biblScope unit="volume">82</biblScope>
                <biblScope unit="issue">04</biblScope>
                <biblScope unit="page">12831</biblScope>
                <date type="published" when="2004" />
                <publisher>Pdf</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b30">
            <analytic>
              <title level="a" type="main">Effects of Prostanoid EP Agonists on Mouse Intraocular Pressure</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tadashiro</forename><surname>Saeki</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takashi</forename><surname>Ota</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Makoto</forename><surname>Aihara</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Makoto</forename><surname>Araie</surname></persName>
              </author>
              <idno type="doi">10.1167/iovs.08-2800</idno>
            </analytic>
            <monogr>
              <title level="j">Investigative Opthalmology &amp; Visual Science</title>
              <title level="j" type="abbrev">Invest. Ophthalmol. Vis. Sci.</title>
              <idno type="ISSN">1552-5783</idno>
              <imprint>
                <biblScope unit="volume">50</biblScope>
                <biblScope unit="issue">5</biblScope>
                <biblScope unit="page">2201</biblScope>
                <date type="published" when="2009-05-01" />
                <publisher>Association for Research in Vision and Ophthalmology (ARVO)</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b31">
            <analytic>
              <title level="a" type="main">Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mayumi</forename><surname>Sakurai</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tomomi</forename><surname>Higashide</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shinji</forename><surname>Ohkubo</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hisashi</forename><surname>Takeda</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kazuhisa</forename><surname>Sugiyama</surname></persName>
              </author>
              <idno type="doi">10.1136/bjophthalmol-2013-304267</idno>
            </analytic>
            <monogr>
              <title level="j">British Journal of Ophthalmology</title>
              <title level="j" type="abbrev">Br J Ophthalmol</title>
              <idno type="ISSN">0007-1161</idno>
              <idno type="ISSNe">1468-2079</idno>
              <imprint>
                <biblScope unit="volume">98</biblScope>
                <biblScope unit="issue">4</biblScope>
                <biblScope unit="page" from="469" to="473" />
                <date type="published" when="2014-04" />
                <publisher>BMJ</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b32">
            <analytic>
              <title level="a" type="main">Glaucoma management: relative value and place in therapy of available drug treatments</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deepak</forename><surname>Sambhara</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ahmad</forename><forename type="middle">A</forename><surname>Aref</surname></persName>
              </author>
              <idno type="doi">10.1177/2040622313511286</idno>
            </analytic>
            <monogr>
              <title level="j">Therapeutic Advances in Chronic Disease</title>
              <title level="j" type="abbrev">Therapeutic Advances in Chronic Disease</title>
              <idno type="ISSN">2040-6223</idno>
              <idno type="ISSNe">2040-6231</idno>
              <imprint>
                <biblScope unit="volume">5</biblScope>
                <biblScope unit="issue">1</biblScope>
                <biblScope unit="page" from="30" to="43" />
                <date type="published" when="2014-01" />
                <publisher>SAGE Publications</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b33">
            <analytic>
              <title level="a" type="main">The mechanism of action of prostaglandins on uveoscleral outflow</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Undine</forename><surname>Schachtschabel</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">D</forename><surname>Lindsey</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">N</forename><surname>Weinreb</surname></persName>
              </author>
              <idno type="doi">10.1097/00055735-200004000-00008</idno>
              <ptr target="https://journals.lww.com/co-ophthalmology/Fulltext/2000/04000/Themechanismofactionofprostaglandinson.8.aspx" />
            </analytic>
            <monogr>
              <title level="j">Current Opinion in Ophthalmology</title>
              <title level="j" type="abbrev">Current Opinion in Ophthalmology</title>
              <idno type="ISSN">1040-8738</idno>
              <imprint>
                <biblScope unit="volume">11</biblScope>
                <biblScope unit="issue">2</biblScope>
                <biblScope unit="page" from="112" to="115" />
                <date type="published" when="2000-04" />
                <publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b34">
            <analytic>
              <title level="a" type="main">A Retrospective Review of Non-Responders to Latanoprost</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Scherer</surname></persName>
              </author>
              <idno type="doi">10.1089/108076802760116205</idno>
            </analytic>
            <monogr>
              <title level="j">Journal of Ocular Pharmacology and Therapeutics</title>
              <title level="j" type="abbrev">Journal of Ocular Pharmacology and Therapeutics</title>
              <idno type="ISSN">1080-7683</idno>
              <idno type="ISSNe">1557-7732</idno>
              <imprint>
                <biblScope unit="volume">18</biblScope>
                <biblScope unit="issue">3</biblScope>
                <biblScope unit="page" from="287" to="291" />
                <date type="published" when="2002-06" />
                <publisher>Mary Ann Liebert Inc</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b35">
            <analytic>
              <title level="a" type="main">NIH Image to ImageJ: 25 years of image analysis</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Caroline</forename><forename type="middle">A</forename><surname>Schneider</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wayne</forename><forename type="middle">S</forename><surname>Rasband</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kevin</forename><forename type="middle">W</forename><surname>Eliceiri</surname></persName>
              </author>
              <idno type="doi">10.1038/nmeth.2089</idno>
              <ptr target="https://www.ncbi.nlm.nih.gov/pubmed/22930834" />
            </analytic>
            <monogr>
              <title level="j">Nature Methods</title>
              <title level="j" type="abbrev">Nat Methods</title>
              <idno type="ISSN">1548-7091</idno>
              <idno type="ISSNe">1548-7105</idno>
              <imprint>
                <biblScope unit="volume">9</biblScope>
                <biblScope unit="issue">7</biblScope>
                <biblScope unit="page" from="671" to="675" />
                <date type="published" when="2012-07" />
                <publisher>Springer Science and Business Media LLC</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b36">
            <analytic>
              <title level="a" type="main">Measurement of Outflow Facility Using iPerfusion</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><forename type="middle">M</forename><surname>Sherwood</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ester</forename><surname>Reina-Torres</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jacques</forename><forename type="middle">A</forename><surname>Bertrand</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barnaby</forename><surname>Rowe</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Darryl</forename><forename type="middle">R</forename><surname>Overby</surname></persName>
              </author>
              <idno type="doi">10.1371/journal.pone.0150694</idno>
            </analytic>
            <monogr>
              <title level="j">PLOS ONE</title>
              <title level="j" type="abbrev">PLoS ONE</title>
              <idno type="ISSNe">1932-6203</idno>
              <imprint>
                <biblScope unit="volume">11</biblScope>
                <biblScope unit="issue">3</biblScope>
                <biblScope unit="page">e0150694</biblScope>
                <date type="published" when="2016" />
                <publisher>Public Library of Science (PLoS)</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b37">
            <analytic>
              <title level="a" type="main">Role of cyclic AMP in the eye with glaucoma</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Myoung</forename><forename type="middle">Sup</forename><surname>Shim</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keun-Young</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won-Kyu</forename><surname>Ju</surname></persName>
              </author>
              <idno type="doi">10.5483/bmbrep.2017.50.2.200</idno>
            </analytic>
            <monogr>
              <title level="j">BMB Reports</title>
              <title level="j" type="abbrev">BMB Reports</title>
              <idno type="ISSN">1976-6696</idno>
              <imprint>
                <biblScope unit="volume">50</biblScope>
                <biblScope unit="issue">2</biblScope>
                <biblScope unit="page" from="60" to="70" />
                <date type="published" when="2017-02-28" />
                <publisher>Korean Society for Biochemistry and Molecular Biology - BMB Reports</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b38">
            <analytic>
              <title/>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Sleath</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Blalock</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Covert</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">C</forename><surname>Skinner</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">W</forename><surname>Muir</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">L</forename><surname>Robin</surname></persName>
              </author>
              <idno type="doi">doi:10.1016/j.ophtha.2011.05.013.The</idno>
            </analytic>
            <monogr>
              <title level="j">Opthalmology</title>
              <imprint>
                <biblScope unit="volume">118</biblScope>
                <biblScope unit="issue">12</biblScope>
                <biblScope unit="page" from="2398" to="2402" />
                <date type="published" when="2012" />
                <publisher>NIH Public Access</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b39">
            <analytic>
              <title level="a" type="main">Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wayne</forename><surname>Stallaert</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arthur</forename><surname>Christopoulos</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michel</forename><surname>Bouvier</surname></persName>
              </author>
              <idno type="doi">10.1517/17460441.2011.586691</idno>
            </analytic>
            <monogr>
              <title level="j">Expert Opinion on Drug Discovery</title>
              <title level="j" type="abbrev">Expert Opinion on Drug Discovery</title>
              <idno type="ISSN">1746-0441</idno>
              <idno type="ISSNe">1746-045X</idno>
              <imprint>
                <biblScope unit="volume">6</biblScope>
                <biblScope unit="issue">8</biblScope>
                <biblScope unit="page" from="811" to="825" />
                <date type="published" when="2011-08" />
                <publisher>Informa Healthcare</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b40">
            <analytic>
              <title level="a" type="main">Novel pentablock copolymer (PLA–PCL–PEG–PCL–PLA)-based nanoparticles for controlled drug delivery: effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Viral</forename><surname>Tamboli</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gyan</forename><forename type="middle">P</forename><surname>Mishra</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ashim</forename><forename type="middle">K</forename><surname>Mitra</surname></persName>
              </author>
              <idno type="doi">10.1007/s00396-012-2854-0</idno>
            </analytic>
            <monogr>
              <title level="j">Colloid and Polymer Science</title>
              <title level="j" type="abbrev">Colloid Polym Sci</title>
              <idno type="ISSN">0303-402X</idno>
              <idno type="ISSNe">1435-1536</idno>
              <imprint>
                <biblScope unit="volume">291</biblScope>
                <biblScope unit="issue">5</biblScope>
                <biblScope unit="page" from="1235" to="1245" />
                <date type="published" when="2013-05" />
                <publisher>Springer Science and Business Media LLC</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b41">
            <analytic>
              <title level="a" type="main">Ciliary body</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ernst</forename><forename type="middle">R</forename><surname>Tamm</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elke</forename><surname>Lütjen-Drecoll</surname></persName>
              </author>
              <idno type="doi">10.1002/(sici)1097-0029(19960401)33:5&lt;390::aid-jemt2&gt;3.0.co;2-s</idno>
            </analytic>
            <monogr>
              <title level="j">Microscopy Research and Technique</title>
              <title level="j" type="abbrev">Microsc. Res. Tech.</title>
              <idno type="ISSN">1059-910X</idno>
              <idno type="ISSNe">1097-0029</idno>
              <imprint>
                <biblScope unit="volume">33</biblScope>
                <biblScope unit="issue">5</biblScope>
                <biblScope unit="page" from="390" to="439" />
                <date type="published" when="1996-04-01" />
                <publisher>Wiley</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b42">
            <analytic>
              <title level="a" type="main">The relationship between outflow resistance and trabecular meshwork stiffness in mice</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ke</forename><surname>Wang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guorong</forename><surname>Li</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">Thomas</forename><surname>Read</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Iris</forename><surname>Navarro</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ashim</forename><forename type="middle">K</forename><surname>Mitra</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">Daniel</forename><surname>Stamer</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Todd</forename><surname>Sulchek</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Ross</forename><surname>Ethier</surname></persName>
              </author>
              <idno type="doi">10.1038/s41598-018-24165-w</idno>
            </analytic>
            <monogr>
              <title level="j">Scientific Reports</title>
              <title level="j" type="abbrev">Sci Rep</title>
              <idno type="ISSNe">2045-2322</idno>
              <imprint>
                <biblScope unit="volume">8</biblScope>
                <biblScope unit="issue">1</biblScope>
                <biblScope unit="page" from="1" to="12" />
                <date type="published" when="2018-12" />
                <publisher>Springer Science and Business Media LLC</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b43">
            <analytic>
              <title level="a" type="main">G Protein–Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stacy</forename><forename type="middle">Gelhaus</forename><surname>Wendell</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hao</forename><surname>Fan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheng</forename><surname>Zhang</surname></persName>
              </author>
              <idno type="doi">10.1124/pr.118.016899</idno>
            </analytic>
            <monogr>
              <title level="j">Pharmacological Reviews</title>
              <title level="j" type="abbrev">Pharmacol Rev</title>
              <idno type="ISSN">0031-6997</idno>
              <idno type="ISSNe">1521-0081</idno>
              <imprint>
                <biblScope unit="volume">72</biblScope>
                <biblScope unit="issue">1</biblScope>
                <biblScope unit="page" from="1" to="49" />
                <date type="published" when="2020-01" />
                <publisher>American Society for Pharmacology &amp; Experimental Therapeutics (ASPET)</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b44">
            <analytic>
              <title level="a" type="main">Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nelson</forename><forename type="middle">S</forename><surname>Winkler</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">P</forename><surname>Fautsch</surname></persName>
              </author>
              <idno type="doi">10.1089/jop.2013.0179</idno>
            </analytic>
            <monogr>
              <title level="j">Journal of Ocular Pharmacology and Therapeutics</title>
              <title level="j" type="abbrev">Journal of Ocular Pharmacology and Therapeutics</title>
              <idno type="ISSN">1080-7683</idno>
              <idno type="ISSNe">1557-7732</idno>
              <imprint>
                <biblScope unit="volume">30</biblScope>
                <biblScope unit="issue">2-3</biblScope>
                <biblScope unit="page" from="102" to="109" />
                <date type="published" when="2014-03" />
                <publisher>Mary Ann Liebert Inc</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b45">
            <analytic>
              <title level="a" type="main">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eric</forename><forename type="middle">A</forename><surname>Wold</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianping</forename><surname>Chen</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kathryn</forename><forename type="middle">A</forename><surname>Cunningham</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jia</forename><surname>Zhou</surname></persName>
              </author>
              <idno type="doi">10.1021/acs.jmedchem.8b00875</idno>
            </analytic>
            <monogr>
              <title level="j">Journal of Medicinal Chemistry</title>
              <title level="j" type="abbrev">J. Med. Chem.</title>
              <idno type="ISSN">0022-2623</idno>
              <idno type="ISSNe">1520-4804</idno>
              <imprint>
                <biblScope unit="volume">62</biblScope>
                <biblScope unit="issue">1</biblScope>
                <biblScope unit="page" from="88" to="127" />
                <date type="published" when="2019-01-10" />
                <publisher>American Chemical Society (ACS)</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b46">
            <analytic>
              <title level="a" type="main">A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">F</forename><surname>Woodward</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jenny</forename><forename type="middle">W</forename><surname>Wang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">A</forename><surname>Coleman</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amanda</forename><forename type="middle">J</forename><surname>Woodrooffe</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenneth</forename><forename type="middle">L</forename><surname>Clark</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">Daniel</forename><surname>Stamer</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guoxian</forename><surname>Tao</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shan</forename><surname>Fan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carol</forename><forename type="middle">B</forename><surname>Toris</surname></persName>
              </author>
              <idno type="doi">10.1089/jop.2018.0126</idno>
            </analytic>
            <monogr>
              <title level="j">Journal of Ocular Pharmacology and Therapeutics</title>
              <title level="j" type="abbrev">Journal of Ocular Pharmacology and Therapeutics</title>
              <idno type="ISSN">1080-7683</idno>
              <idno type="ISSNe">1557-7732</idno>
              <imprint>
                <biblScope unit="volume">35</biblScope>
                <biblScope unit="issue">5</biblScope>
                <biblScope unit="page" from="265" to="277" />
                <date type="published" when="2019-06" />
                <publisher>Mary Ann Liebert Inc</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b47">
            <analytic>
              <title level="a" type="main">Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">F</forename><surname>Woodward</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jenny</forename><forename type="middle">W</forename><surname>Wang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">Daniel</forename><surname>Stamer</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Lütjen-Drecoll</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Null-</forename><forename type="middle">P</forename><surname>Krauss</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carol</forename><forename type="middle">B</forename><surname>Toris</surname></persName>
              </author>
              <idno type="doi">10.1089/jop.2019.0041</idno>
            </analytic>
            <monogr>
              <title level="j">Journal of Ocular Pharmacology and Therapeutics</title>
              <title level="j" type="abbrev">Journal of Ocular Pharmacology and Therapeutics</title>
              <idno type="ISSN">1080-7683</idno>
              <idno type="ISSNe">1557-7732</idno>
              <imprint>
                <biblScope unit="volume">35</biblScope>
                <biblScope unit="issue">9</biblScope>
                <biblScope unit="page" from="469" to="474" />
                <date type="published" when="2019-11-01" />
                <publisher>Mary Ann Liebert Inc</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b48">
            <analytic>
              <title level="a" type="main">Glucocorticoid Receptor-Mediated Suppression of Activator Protein-1 Activation and Matrix Metalloproteinase Expression after Spinal Cord Injury</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jan</forename><surname>Xu</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gyeong-Moon</forename><forename type="middle">M</forename><surname>Kim</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">Hinan</forename><surname>Ahmed</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jinming</forename><surname>Xu</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ping</forename><surname>Yan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao</forename><forename type="middle">Ming</forename><surname>Xu</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chung</forename><forename type="middle">Y</forename><surname>Hsu</surname></persName>
              </author>
              <idno type="doi">10.1523/jneurosci.21-01-00092.2001</idno>
            </analytic>
            <monogr>
              <title level="j">The Journal of Neuroscience</title>
              <title level="j" type="abbrev">J. Neurosci.</title>
              <idno type="ISSN">0270-6474</idno>
              <idno type="ISSNe">1529-2401</idno>
              <imprint>
                <biblScope unit="volume">21</biblScope>
                <biblScope unit="issue">1</biblScope>
                <biblScope unit="page" from="92" to="97" />
                <date type="published" when="2001-01-01" />
                <publisher>Society for Neuroscience</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b49">
            <analytic>
              <title level="a" type="main">Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma</title>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhou</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">R</forename><surname>Patel</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">W</forename><surname>Sirianni</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Strohbehn</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-Q</forename><forename type="middle">Q</forename><surname>Zheng</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Duong</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Schafbauer</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Huttner</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Huang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Carson</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Zhang</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Sullivan</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Piepmeier</surname></persName>
              </author>
              <author>
                <persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">M</forename><surname>Saltzman</surname></persName>
              </author>
              <idno type="doi">10.1073/pnas.1304504110</idno>
            </analytic>
            <monogr>
              <title level="j">Proceedings of the National Academy of Sciences</title>
              <title level="j" type="abbrev">Proceedings of the National Academy of Sciences</title>
              <idno type="ISSN">0027-8424</idno>
              <idno type="ISSNe">1091-6490</idno>
              <imprint>
                <biblScope unit="volume">110</biblScope>
                <biblScope unit="issue">29</biblScope>
                <biblScope unit="page" from="11751" to="11756" />
                <date type="published" when="2013-07-16" />
                <publisher>Proceedings of the National Academy of Sciences</publisher>
              </imprint>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b50">
            <monogr>
              <title level="m" type="main">Supplemental Figure 1: IOP (A) and outflow facility(B) in Ptger2 +/+ mice andPtger2 -/-littermates</title>
              <imprint/>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b51">
            <monogr>
              <title level="m" type="main">Representative genotyping result fromPtger2 -/-(300 base pairs) and littermatePtger2 +/+ mice (165 base pairs), ladder is 1 kb. The presentation of data in panels A and B is as described in Figures 1 and 2 of the main text</title>
              <imprint/>
            </monogr>
          </biblStruct>

          <biblStruct xml:id="b52">
            <analytic>
              <title level="a" type="main">A) IOP elevation in response to dexamethasone loaded nanoparticles. (B) Body weight of the mice was unaffected by the steroids, increasing from a mean of 25.7 [25, 26] grams to 27.9 [27, 29] grams over the duration of the study. The presentation of data in panels A and B is as described in Figures 1 and 2 of the main text</title>
            </analytic>
            <monogr>
              <title level="j">Supplemental Figure</title>
              <imprint>
                <biblScope unit="volume">2</biblScope>
              </imprint>
            </monogr>
            <note>with grey lines connecting paired data at different time points</note>
          </biblStruct>

          <biblStruct xml:id="b53">
            <monogr>
              <title level="m" type="main">IOP elevation in response to dexamethasone loaded nanoparticles forPtger2 -/-and littermatePtger2 +/+ mice. (B) Body weight of the mice was unaffected by the steroids. The presentation of data in panels A and B is as described in Figures 1 and 2 of the main text</title>
              <imprint/>
            </monogr>
            <note>Supplemental Figure 4: (A. with grey lines connecting paired data at different time points</note>
          </biblStruct>

        </listBibl>
      </div>
    </back>
  </text>
</TEI>
